First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
2018
TPS2619Background: NOTCH signalling is a key development pathway whose aberrant activation is recognised to play an oncogenic role in human cancers. When NOTCH signalling is inappropriately activat...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
5
Citations
NaN
KQI